ClinicalTrials.gg
CompletedNCT02028754RLOTUSUpdated Apr 23, 2014Results posted

A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

A Phase 4 interventional study of Sodium Carboxymethylcellulose and Levofloxacin in Dry Eye Syndromes and Cataract, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-04-23.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. carboxymethylcellulose · Dry Eye Syndromes.

Enrollment
2nd of 11
180 · median 80
Started
2011
with 1 other
Phase 4
11 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
5 of 12
Allergan

Among the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 4, and was the 8th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 12 studies testing carboxymethylcellulose in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About carboxymethylcellulose

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing carboxymethylcellulose in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study will evaluate the effect of sodium carboxymethylcellulose eye drops in the treatment of dry eye after cataract surgery.

03

Conditions studied

  • Dry Eye Syndromes
  • Cataract
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of age-related cataract in the study eye
  • Scheduled for cataract surgery and lens implant

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ocular surface disease or glaucoma
  • Ocular surgery in the past 3 months
  • Wearing a corneal contact lens in the study eye
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Sodium Carboxymethylcellulose and Conventional Therapy

    Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.

    Drug: Sodium Carboxymethylcellulose · Drug: Levofloxacin · Drug: Prednisolone

  • Active comparator
    Conventional Therapy

    Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.

    Drug: Levofloxacin · Drug: Prednisolone

Interventions

  • Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.

    Also known as: Refresh Liquigel®

  • Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.

    Also known as: Cravit®

  • Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.

    Also known as: PRED FORTE®

06

What researchers measure

Primary outcomes

  1. Tear Break-Up Time (TBUT) in the Study Eye

    TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

    Time frame: Day 7

  2. Tear Break-Up Time (TBUT) in the Study Eye

    TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

    Time frame: Day 30

Secondary outcomes

  1. Fluorescein Staining Score in the Study Eye

    The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.

    Time frame: Day 7, Day 30

  2. Lissamine Green Staining Score in the Study Eye

    Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.

    Time frame: Day 7, Day 30

  3. Results of Schirmer I Test With Anesthetics in the Study Eye

    The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.

    Time frame: Day 7, Day 30

  4. Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye

    The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).

    Time frame: Day 7, Day 30

  5. Subjective Symptom Total Score in the Study Eye

    The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).

    Time frame: Day 7, Day 30

07

Results

Posted Apr 23, 2014

Participant flow

Participant flow — Overall Study
MilestoneSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Started9090
Completed8382
Not completed78

Outcome measures

PrimaryTear Break-Up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

Time frame:
Day 7
Reported as:
Mean · Seconds
Tear Break-Up Time (TBUT) in the Study Eye
SecondsSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Tear Break-Up Time (TBUT) in the Study Eye8.5 ± 5.56.6 ± 3.8
PrimaryTear Break-Up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the study eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film.

Time frame:
Day 30
Reported as:
Mean · Seconds
Tear Break-Up Time (TBUT) in the Study Eye
SecondsSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Tear Break-Up Time (TBUT) in the Study Eye9.0 ± 5.96.7 ± 4.8
SecondaryFluorescein Staining Score in the Study Eye

The cornea is evaluated following ocular administration of fluorescein stain in the study eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The cornea is divided into 3 regions. Each region is scored according to the extent of staining, with scores ranging from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the cornea, 2=staining range ≥ 1/2 of the cornea, and 3=regional whole staining of the cornea. The total score ranges from 0 to 9 points. The higher the staining score, the worse the dry eye condition.

Time frame:
Day 7, Day 30
Reported as:
Mean · Scores on a Scale
Fluorescein Staining Score in the Study Eye
Scores on a ScaleSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Day 72.0 ± 2.81.8 ± 2.6
Day 30 (N=83, 82)1.1 ± 1.81.2 ± 1.9
SecondaryLissamine Green Staining Score in the Study Eye

Conjunctival and corneal staining are evaluated following ocular administration of lissamine green dye in the study eye. The conjunctiva is the clear membrane covering the white surface of the eye. The cornea is the transparent front part of the eye which covers the iris and pupil. The conjunctiva and cornea are divided into 5 regions that are scored based on the extent of staining. Scores range from 0 to 3 points: 0=non-staining, 1=staining range \< 1/2 of the conjunctiva and cornea, 2=staining range ≥ 1/2 of the conjunctiva and cornea, and 3=regional whole staining of the conjunctiva and cornea. The total score ranges from 0 to 15 points. The higher the grade score, the worse the dry eye condition.

Time frame:
Day 7, Day 30
Reported as:
Mean · Scores on a Scale
Lissamine Green Staining Score in the Study Eye
Scores on a ScaleSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Day 72.9 ± 3.32.6 ± 3.2
Day 30 (N=83,82)2.1 ± 2.42.3 ± 2.6
SecondaryResults of Schirmer I Test With Anesthetics in the Study Eye

The Schirmer I test consists of anesthetic drops being placed into the lower eyelid of the study eye. Patients then close their eyes. Test paper is placed on the lower eyelid of the patient's closed eyes. The paper is then removed and the moisture length on the paper recorded. Shorter distances indicate worse dry eye symptoms.

Time frame:
Day 7, Day 30
Reported as:
Mean · Millimeters
Results of Schirmer I Test With Anesthetics in the Study Eye
MillimetersSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Day 711.8 ± 5.612.5 ± 6.8
Day 30 (N=83, 82)12.7 ± 6.112.6 ± 6.5
SecondaryOcular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye

The OSDI is a 12-question survey for patients to document their dry eye disease symptoms in the study eye. The OSDI consists of a 5-point scale (0=none of the time and 4 = all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability).

Time frame:
Day 7, Day 30
Reported as:
Mean · Scores on a Scale
Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye
Scores on a ScaleSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Day 715.6 ± 16.818.1 ± 19.5
Day 30 (N=83, 82)12.7 ± 11.314.2 ± 13.8
SecondarySubjective Symptom Total Score in the Study Eye

The following 11 subjective symptoms are evaluated in the study eye: foreign body sensation, photophobia, itching, pain in the eye, dry eye, eye heaviness, blurred vision, eye fatigue, eye discomfort, eye secretions and tears. Each of these symptoms is divided into 4 classes: no symptom=0; occasional symptoms=1; intermittent mild symptoms=2; and persistent obvious symptoms=3. The total score ranged from 0 (best) to 33 (worst).

Time frame:
Day 7, Day 30
Reported as:
Mean · Scores on a Scale
Subjective Symptom Total Score in the Study Eye
Scores on a ScaleSodium Carboxymethylcellulose and Conventional TherapyConventional Therapy
Day 76.1 ± 5.36.4 ± 5.2
Day 30 (N=83, 82)5.1 ± 3.65.6 ± 4.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Carboxymethylcellulose and Conventional Therapy—0/86 (0%)0/86 (0%)
Conventional Therapy—0/85 (0%)0/85 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sodium Carboxymethylcellulose and Conventional TherapyConventional TherapyTotal
Mean68.8 ± 7.169.0 ± 7.168.9 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Carboxymethylcellulose and Conventional TherapyConventional TherapyTotal
Female5459113
Male363167
08

Study locations

1 site
  • Hangzhou, China
09

References and documents

Publications

  • Yao K, Bao Y, Ye J, Lu Y, Bi H, Tang X, Zhao Y, Zhang J, Yang J. Efficacy of 1% carboxymethylcellulose sodium for treating dry eye after phacoemulsification: results from a multicenter, open-label, randomized, controlled study. BMC Ophthalmol. 2015 Mar 20;15:28. doi: 10.1186/s12886-015-0005-3. PubMed 25880685 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2014
First posted
Jan 7, 2014
Start
Jul 2011
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Apr 23, 2014
Last update
Apr 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02028754
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jan 7, 2014
Start date
Jul 2011
Primary completion
May 2013
Completion
May 2013
Results posted
Apr 23, 2014
Last update
Apr 23, 2014

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboxymethylcellulose

Start the discussion